2,461,018 Shares in Elanco Animal Health Incorporated $ELAN Bought by Artemis Investment Management LLP

Key Points

• Artemis Investment Management LLP bought a new position of 2,461,018 shares in Elanco Animal Health, valued at about $55.7 million and representing roughly 0.50% of the company.
• Wall Street sentiment has turned more positive with several upgrades; the stock carries an average analyst rating of Moderate Buy and an average price target of $27.90.
• Elanco beat Q4 revenue and EPS expectations (revenue $1.14B, EPS $0.13), reported 12.2% YoY revenue growth, and issued Q1 2026 guidance of $0.33–$0.36 and FY2026 guidance of $1.00–$1.06.

Artemis Investment Management LLP bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 2,461,018 shares of the company's stock, valued at approximately $55,693,000. Artemis Investment Management LLP owned about 0.50% of Elanco Animal Health at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. grew its stake in Elanco Animal Health by 2,563.5% during the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company's stock valued at $28,000 after purchasing an additional 1,333 shares during the last quarter. Huntington National Bank grew its stake in Elanco Animal Health by 136.7% during the 3rd quarter. Huntington National Bank now owns 1,882 shares of the company's stock valued at $38,000 after purchasing an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company's stock valued at $42,000 after purchasing an additional 900 shares during the last quarter. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 79.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company's stock valued at $43,000 after purchasing an additional 951 shares during the last quarter. Finally, Torren Management LLC purchased a new stake in Elanco Animal Health during the 4th quarter valued at about $46,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts have weighed in on ELAN shares. Piper Sandler upgraded Elanco Animal Health from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $24.00 to $30.00 in a research note on Thursday, January 22nd. JPMorgan Chase & Co. boosted their price target on Elanco Animal Health from $24.00 to $28.00 and gave the company an "overweight" rating in a research note on Thursday, February 19th. Citigroup started coverage on Elanco Animal Health in a research note on Wednesday, April 15th. They set a "buy" rating and a $30.00 price target on the stock. UBS Group reiterated a "buy" rating on shares of Elanco Animal Health in a research note on Tuesday, March 10th. Finally, Weiss Ratings upgraded Elanco Animal Health from a "sell (d)" rating to a "sell (d+)" rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $27.90.

Elanco Animal Health Price Performance

Elanco Animal Health stock opened at $22.54 on Friday. The company has a current ratio of 2.17, a quick ratio of 1.08 and a debt-to-equity ratio of 0.60. The company has a 50-day moving average price of $23.86 and a 200 day moving average price of $23.23. Elanco Animal Health Incorporated has a 12-month low of $9.42 and a 12-month high of $27.72. The stock has a market cap of $11.21 billion, a P/E ratio of -46.96, a PEG ratio of 2.85 and a beta of 1.69.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.09 billion. During the same period in the previous year, the business posted $0.14 EPS. Elanco Animal Health's revenue was up 12.2% on a year-over-year basis. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. Sell-side analysts anticipate that Elanco Animal Health Incorporated will post 1.03 earnings per share for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.